Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
London, February 25
26 February 2020
AfriAg Global PLC
(‘AfriAg’ or the ‘Company’)
Update on Apollon UK Acquisition
AfriAg Global PLC, a company whose shares are admitted to trading on London’s NEX Exchange, is pleased to provide an update on the proposed acquisition of Apollon Formularies Ltd (“Apollon UK”). The Company currently owns 2.68% of the share capital of Apollon UK and is working with Apollon UK to satisfy all regulatory requirements for the proposed acquisition of the entire issued share capital of Apollon UK (the “Acquisition”). In due course, subject to making an offer to the shareholders of Apollon UK and obtaining the necessary approvals, the Company intends to send an explanatory circular and notice of general meeting to its shareholders seeking approval of the Acquisition.
It is intended that the Company will acquire all the issued and outstanding shares from the shareholders of Apollon UK pursuant to a right of first refusal in consideration for the issue and allotment to those shareholders of new ordinary shares in the capital of the Company at a price of 10 pence per new ordinary share.
Apollon UK is entitled to 95% of the net profit of Apollon Formularies Jamaica, Limited (“Apollon Jamaica”). Subject to approval from the Cannabis Licensing Authority in Jamaica , Apollon UK has the right to acquire a 49% interest in the issued share capital of Apollon Jamaica .
Apollon Jamaica holds the following licenses:
- Licence to cultivate cannabis for the sole purposes of undertaking research, including clinical research as approved by the Ministry of Health;
- License to process and manufacture any cannabis based products that have been approved by the Ministry of Health for medical, therapeutic and scientific purposes (Processing Licence 170209113513) at designated premises of Apollon Jamaica ; and
- License to provide therapeutic services using cannabis (Retail (Therapeutic Services) Licence 170209153635).
The directors of the Company accept responsibility for the contents of this announcement.
-ENDS-
For further information on AfriAg Global please visit the www.afriagglobal.com or please contact;